https://helocyte.com/data-from-phase-1-trial-of-triplex-vaccine-for-control-of-cytomegalovirus-published-in-blood/2017-02-07T20:38:41+00:00https://helocyte.com/helocyte-announces-corporate-and-clinical-milestones/2017-02-07T20:26:26+00:00https://helocyte.com/fortress-biotech-fka-coronado-biosciences-forms-new-subsidiary-helocyte-inc-fka-diavax-biosciences-to-develop-novel-immunotherapies-for-cytomegalovirus/2017-02-07T20:26:37+00:00https://helocyte.com/fortress-biotech-announces-initiation-of-phase-2-clinical-trial-of-triplex-for-adults-co-infected-with-hiv-and-cmv/2021-12-16T13:41:28+00:00https://helocyte.com/study-published-in-american-journal-of-hematology-demonstrates-first-reported-evidence-of-safe-and-successful-boosting-of-cytomegalovirus-vaccine-specific-t-cell-immunity-in-a-stem-cell-transplant-rec/2023-02-16T13:07:41+00:00https://helocyte.com/helocyte-inc-announces-positive-data-from-stem-cell-transplant-donor-vaccination-trial-to-be-presented-at-the-2023-tandem-meetings-transplantation-cellular-therapy-meetings-of-astct-and-cibmtr/2023-02-16T13:34:26+00:00https://helocyte.com/helocyte-announces-3-22-million-grant-from-the-national-cancer-institute-for-triplex-phase-2-clinical-trial-program/2023-06-15T12:06:07+00:00https://helocyte.com/fortress-biotech-subsidiary-helocyte-announces-option-agreement-with-city-of-hope-for-exclusive-worldwide-rights-to-use-a-novel-bispecific-cmv-hiv-car-t-cell-therapy-optionally-in-combination-with-tr/2023-10-16T13:05:59+00:00https://helocyte.com/fortress-biotech-subsidiary-helocyte-announces-grant-that-could-provide-over-20-million-from-national-institute-of-allergy-and-infectious-diseases-for-phase-2-study-of-triplex-for-control-of-cytomega/2023-12-12T18:50:56+00:00https://helocyte.com/fortress-biotech-announces-first-patient-dosed-in-multi-center-phase-2-study-of-triplex-for-control-of-cmv-in-patients-undergoing-liver-transplantation/2024-05-15T12:03:33+00:00https://helocyte.com/fortress-biotech-announces-first-patient-dosed-in-phase-2-clinical-trial-of-triplex-vaccination-in-stem-cell-donors-to-reduce-cmv-events-in-recipients-of-hsct/2025-01-27T13:31:16+00:00